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BACKGROUND/INTRODUCTION 
• Daptomycin is a lipopeptide antibiotic indicated for the treatment of complicated 
skin and skin structure infections, bacteremia resulting from Staphylococcus 
aureus, and right-sided infective endocarditis.2 
• There are multiple studies that support the use of adjusted body weight dosing for 
daptomycin in obese patients. 2 The data from one study reported an increase of 
creatinine phosphokinase (CPK) in obese patients that were dosed based on actual 
body weight.1
• At South Miami Hospital (SMH), there is a daptomycin dosing protocol that was 
revised. Now, pharmacists are to use adjusted body weight to dose patients with a 
body mass index (BMI) above 30 kg/m2 and/or total body weight (TBW) above 20% 
of their ideal body weight (IBW). 
• This study was developed to identify the benefits of following the new daptomycin 
protocol. 
OBJECTIVES
• The data was evaluated in order to: 
• Analyze the difference in patients’ length of stay at the hospital. 
• Calculate the cost savings subsequent to the new protocol. 
• Compare CPK levels for those patients included post-protocol.
METHODS 
• This is a retrospective study that was approved by the Baptist Health South 
Florida Institutional Review Board. 
• The study analyzed fifty electronic medical administration records of randomly 
selected patients. 
• An electronic report was generated, including patients that were treated with 
daptomycin from 02/01/2018 – 10/01/2018. All patients were eighteen years of 
age or older and had a total body weight of greater than twenty percent of their 
ideal body weight. 
• Twenty-five patient reports were compared prior to the protocol implementation 
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Average Days on Daptomycin Therapy  
• A total of forty seven (47) patients were included in this study. Out of those 47 
patients, 25 were treated with daptomycin prior to the revision of the protocol 
and the remaining 22 were subsequent to the protocol revision. 
• The average length of stay for the patients treated with daptomycin prior to the 
revision of the protocol was 10.4 days, and 13.6 days post-protocol revision. 
• Duration of therapy for daptomycin was similar among the two studied groups. 
Patients prior to the protocol revision were treated for an average of 4.04 days 
and patients after the protocol revision were treated for 3.77 days on average. 
• The average CPK level for patients prior to the protocol revision was 117.95 U/L, 
versus 154.32 U/L for patients after the implementation of the revised protocol. 
There was an outlier in the post-protocol group with a CPK level of 1,620 U/L. This 
elevated level may be attributed to factors other than daptomycin. This one 
patient had an elevated temperature of 39.4 degrees Celsius in combination with 
osteomyelitis. 
• Overall, the estimated cost of therapy was lower in the post-protocol revision 
group $14,469.85 (n=22), compared to $19,584.41 (n=25) prior to the protocol 
revision. The estimated cost savings in the study period was $5,115.56.  
• Limitations of this study were the small sample size, short-term study period, and 
a lack of direct correlation between daptomycin therapy and length of stay.  
• The average duration of therapy for both study groups did not differ significantly 
in this study. This supports the existing literature stating that using adjusted 
body weight to dose overweight patients does not decrease the effectiveness of 
daptomycin. 
• The protocol that is utilized at SMH proposes benefit not only for the patient but 
also for the institution.  These benefits include decreasing unnecessary exposure 
to higher doses of daptomycin for patients and cost savings for the institution. 
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